POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER).

How it works

Potassium chloride dissociates into potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse transmission, cardiac contractility, and acid-base balance. Replacement of potassium corrects hypokalemia.

What the body does with it

Metabolism	Potassium is not metabolized; it is primarily excreted renally (90%) via passive glomerular filtration and active secretion in the distal tubules. Minor losses occur via feces and sweat.
Excretion	Renal excretion is the primary route; >90% of potassium is excreted by the kidneys, with a small amount lost in feces (via gastrointestinal secretion) and negligible biliary excretion. Renal elimination is regulated by aldosterone and tubular secretion.
Half-life	Potassium chloride does not have a classic elimination half-life as it is an endogenous electrolyte. The terminal half-life of exogenous potassium is approximately 2-3 hours in healthy individuals, reflecting rapid cellular uptake and renal clearance. In renal impairment, half-life is prolonged.
Protein binding	Potassium is not significantly protein-bound; <1% is bound to plasma proteins. It exists primarily as free ions in plasma.
Volume of Distribution	Approximately 0.5-0.6 L/kg in adults, reflecting distribution into total body water. Potassium is predominantly intracellular; the apparent Vd is low due to rapid cellular uptake. Clinical meaning: a large Vd would indicate poor cellular uptake or loss from cells.
Bioavailability	Oral potassium chloride has a bioavailability of approximately 90-100% as it is well absorbed from the gastrointestinal tract. Intravenous potassium chloride has 100% bioavailability.
Onset of Action	Intravenous administration: immediate onset (within seconds to minutes) as potassium distributes into extracellular fluid. Oral administration: onset of action occurs within 1-2 hours, as absorption and cellular uptake take time.
Duration of Action	Intravenous: effect lasts as long as infusion continues and for a short period after (minutes to hours), depending on distribution and elimination. Oral: duration is several hours, typically 4-6 hours, depending on dose and renal function.

Classification & Brands

Dosing & administration

20-40 mEq potassium chloride intravenously per dose, infused at a rate not exceeding 10 mEq/hour (or 20 mEq/hour in critical care settings), repeated as needed based on serum potassium levels. Maximum daily dose typically 200 mEq.

Dosage form	INJECTABLE
Renal impairment	GFR 30-59 mL/min: Administer with caution, reduce dose by 25-50% and monitor potassium closely. GFR <30 mL/min: Contraindicated or use only if severely deficient with extreme caution; reduce dose by at least 50% and avoid sustained release formulations. Hemodialysis: Use only with close monitoring; typical dose 10-20 mEq per session.
Liver impairment	Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 25% and monitor potassium. Child-Pugh C: Avoid use unless potassium severely deficient; reduce dose by at least 50% with frequent monitoring.
Pediatric use	Intravenous dose: 0.5-1 mEq/kg/dose, infused at a rate not exceeding 0.5-1 mEq/kg/hour, maximum single dose 20 mEq. For mild hypokalemia: 0.5-1 mEq/kg/day divided. For severe: up to 2 mEq/kg/day with monitoring. Not to exceed 1 mEq/kg/hour or 20 mEq/hour.
Geriatric use	Start at lower end of adult dosing (10-20 mEq) due to increased risk of hyperkalemia and renal impairment. Maximum infusion rate 10 mEq/hour. Use with caution and monitor potassium levels frequently; avoid potassium-sparing diuretics and ACE inhibitors.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER).

Breastfeeding	Potassium is a normal constituent of breast milk. Intravenous potassium chloride administration does not significantly alter milk potassium concentration. M/P ratio not established but expected to be <1. Considered compatible with breastfeeding.
Teratogenic Risk	No evidence of teratogenicity in first trimester. Physiological potassium homeostasis is critical; severe maternal hypokalemia may increase risk of fetal adverse effects. No dose-limiting fetal toxicity reported.

Warnings & precautions

■ FDA Black Box Warning

Potassium chloride injection concentrate must be diluted before use. Rapid infusion or high concentrations may cause fatal hyperkalemia, cardiac arrest, or arrhythmias. Intravenous administration must be via a large-bore vein with continuous cardiac monitoring.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hyperkalemia","Severe renal failure with oliguria/anuria","Addison's disease","Acute dehydration","Heat cramps","Concurrent potassium-sparing diuretics","Patients on spironolactone, eplerenone, or amiloride"]

Clinical Precautions

Precautions

["Risk of hyperkalemia in renal impairment","Avoid in severe renal failure with oliguria","Monitor serum potassium and ECG during IV administration","Use with caution in patients with cardiac disease, adrenal insufficiency, or metabolic acidosis","Extravasation may cause tissue necrosis"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Potassium is not metabolized; it is primarily excreted renally (90%) via passive glomerular filtration and active secretion in the distal tubules. Minor losses occur via feces and sweat.
Excretion	Renal excretion is the primary route; >90% of potassium is excreted by the kidneys, with a small amount lost in feces (via gastrointestinal secretion) and negligible biliary excretion. Renal elimination is regulated by aldosterone and tubular secretion.
Half-life	Potassium chloride does not have a classic elimination half-life as it is an endogenous electrolyte. The terminal half-life of exogenous potassium is approximately 2-3 hours in healthy individuals, reflecting rapid cellular uptake and renal clearance. In renal impairment, half-life is prolonged.
Protein binding	Potassium is not significantly protein-bound; <1% is bound to plasma proteins. It exists primarily as free ions in plasma.
Volume of Distribution	Approximately 0.5-0.6 L/kg in adults, reflecting distribution into total body water. Potassium is predominantly intracellular; the apparent Vd is low due to rapid cellular uptake. Clinical meaning: a large Vd would indicate poor cellular uptake or loss from cells.
Bioavailability	Oral potassium chloride has a bioavailability of approximately 90-100% as it is well absorbed from the gastrointestinal tract. Intravenous potassium chloride has 100% bioavailability.
Onset of Action	Intravenous administration: immediate onset (within seconds to minutes) as potassium distributes into extracellular fluid. Oral administration: onset of action occurs within 1-2 hours, as absorption and cellular uptake take time.
Duration of Action	Intravenous: effect lasts as long as infusion continues and for a short period after (minutes to hours), depending on distribution and elimination. Oral: duration is several hours, typically 4-6 hours, depending on dose and renal function.

Classification & Brands

Dosing & administration

Dosage form	INJECTABLE
Renal impairment	GFR 30-59 mL/min: Administer with caution, reduce dose by 25-50% and monitor potassium closely. GFR <30 mL/min: Contraindicated or use only if severely deficient with extreme caution; reduce dose by at least 50% and avoid sustained release formulations. Hemodialysis: Use only with close monitoring; typical dose 10-20 mEq per session.
Liver impairment	Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 25% and monitor potassium. Child-Pugh C: Avoid use unless potassium severely deficient; reduce dose by at least 50% with frequent monitoring.
Pediatric use	Intravenous dose: 0.5-1 mEq/kg/dose, infused at a rate not exceeding 0.5-1 mEq/kg/hour, maximum single dose 20 mEq. For mild hypokalemia: 0.5-1 mEq/kg/day divided. For severe: up to 2 mEq/kg/day with monitoring. Not to exceed 1 mEq/kg/hour or 20 mEq/hour.
Geriatric use	Start at lower end of adult dosing (10-20 mEq) due to increased risk of hyperkalemia and renal impairment. Maximum infusion rate 10 mEq/hour. Use with caution and monitor potassium levels frequently; avoid potassium-sparing diuretics and ACE inhibitors.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER).

Breastfeeding	Potassium is a normal constituent of breast milk. Intravenous potassium chloride administration does not significantly alter milk potassium concentration. M/P ratio not established but expected to be <1. Considered compatible with breastfeeding.
Teratogenic Risk	No evidence of teratogenicity in first trimester. Physiological potassium homeostasis is critical; severe maternal hypokalemia may increase risk of fetal adverse effects. No dose-limiting fetal toxicity reported.